Arcutis Expands ZORYVE Data Across Pediatric and Psoriasis Indications
Event summary
- Arcutis presented Phase 2 data for ZORYVE cream 0.05% in infants aged 3 to <24 months with atopic dermatitis, showing 34.4% achieving vIGA-AD Success at 4 weeks.
- ZORYVE foam 0.3% demonstrated superior efficacy in scalp and body psoriasis vs. vehicle in the Phase 3 ARRECTOR trial.
- Real-world research revealed 78.8% of adults and 77.6% of caregivers treat chronic skin conditions reactively rather than proactively.
- Collaborative research identified seborrheic dermatitis as primarily Th17-mediated with distinct inflammatory pathways.
- ZORYVE cream 0.05% for infants 3 to <24 months has a PDUFA target action date of February 23, 2027.
The big picture
Arcutis is strengthening ZORYVE's clinical profile across age groups and indications, particularly in underserved pediatric populations. The real-world data on corticosteroid use highlights an opportunity for steroid-sparing alternatives like ZORYVE in chronic dermatology. With ZORYVE already the top-prescribed branded therapy in its categories, these developments could further solidify its market position as dermatologists seek more targeted treatment options.
What we're watching
- Regulatory Approval
- Whether the FDA will approve ZORYVE cream 0.05% for infants by the February 2027 PDUFA date, expanding its addressable market.
- Market Differentiation
- How Arcutis positions ZORYVE against topical corticosteroids given growing patient/caregiver hesitancy about steroid use.
- Pipeline Expansion
- The pace at which Arcutis advances its understanding of seborrheic dermatitis pathophysiology to develop targeted therapies.